Trial Profile
A Phase II, Open-label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rilparencel (Primary)
- Indications Renal failure; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors ProKidney; RegenMed
- 30 Mar 2021 Status changed from completed to discontinued.
- 07 Aug 2017 Status changed from recruiting to completed.
- 14 Jul 2016 Status changed from not yet recruiting to recruiting.